[Treatment options in monogenic disorders of keratinization].
van de Kerkhof
Peter C M
PC
D017255:Acitretin / Q000008:administration & dosage / Q000627:therapeutic use; D002117:Calcitriol / Q000031:analogs & derivatives / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004439:Eccrine Glands; D005782:Gels; D006222:Hamartoma / Q000188:drug therapy; D006801:Humans; D016112:Ichthyosis Vulgaris / Q000188:drug therapy; D016114:Ichthyosis, X-Linked / Q000188:drug therapy / Q000235:genetics; D007645:Keratoderma, Palmoplantar / Q000188:drug therapy; D007641:Keratolytic Agents / Q000627:therapeutic use*; D007642:Keratosis / Q000188:drug therapy* / Q000235:genetics; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D009824:Ointments; D017499:Porokeratosis / Q000188:drug therapy*; D012176:Retinoids / Q000008:administration & dosage / Q000627:therapeutic use; D013543:Sweat Gland Diseases / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome
D003879:Dermatologic Agents; D005782:Gels; D007641:Keratolytic Agents; D009539:Nicotinic Acids; D009824:Ointments; D012176:Retinoids; C055085:calcipotriene; C086827:tazarotene; D002117:Calcitriol; D017255:Acitretin